欢迎您加入月均活跃用户100万＋的科研社区！如您有任何系统建议，请；如有合作推广需求，请点此洽谈。
| 近期推荐： | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 新 Wiley有奖征集：科研生涯第一篇 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Expert Opinion On Drug Safety EXPERT OPIN DRUG SAF （此期刊被最新的JCR期刊SCIE收录） LetPub评分 6.4
54人评分
我要评分
声誉 7.6 影响力 5.3 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 1474-0338 | 
蝌蝌APP，让您与同行交流更轻松
 立即下载 | ||||||||||||||||||||
| E-ISSN | 1744-764X | |||||||||||||||||||||
| 2024-2025最新影响因子 （数据来源于搜索引擎） | 3.1 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2025年5月19日：3.1 | |||||||||||||||||||||
| 2024-2025自引率 | 9.70%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 3.1 | |||||||||||||||||||||
| JCI期刊引文指标 | 0.63 | |||||||||||||||||||||
| h-index | 62 | |||||||||||||||||||||
| CiteScore （ 2025年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://www.tandfonline.com/loi/ieds20#.V48bfkz9cSQ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/eods | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Expert Opinion On Drug Safety的语言要求，还能让Expert Opinion On Drug Safety编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Expert Opinion On Drug Safety编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | INFORMA HEALTHCARE, TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON, ENGLAND, EC2A 4LQ | |||||||||||||||||||||
| 出版商 | Taylor and Francis Ltd. | |||||||||||||||||||||
| 涉及的研究方向 | 医学-药学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Bimonthly | |||||||||||||||||||||
| 出版年份 | 2002 | |||||||||||||||||||||
| 年文章数 | 282点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 10.91% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 82.27% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2024-2025年最新版） | WOS分区等级：2区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2025年3月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月升级版） |
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1474-0338%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 较慢,6-12周 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Expert Opinion On Drug Safety顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Adverse events associated with acute pancreatitis caused by immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database Author: Tong, Lihua; Yuan, Yanling; He, Wanming; Yang, Wen; Pan, Xingxi Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2486311 PubMed DOI |
| 2. | Post-marketing safety associated with sodium zirconium cyclosilicate: a pharmacovigilance study based on the FDA reporting system Author: Chen, Jiankang; Lu, Zuzhuang; Luo, Honghong; Wang, Tiaomin; Qin, Xiaoying Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2486310 PubMed DOI |
| 3. | Infection toxicity assessment of tumor necrosis factor α inhibitors in the treatment of IBD: a real-world study based on the US food and drug administration adverse events reporting system (FAERS) Author: Cheng, Qian; Yao, Zeyu; Shi, Xuan; Zou, Shupeng; Zhao, Yazheng; Ouyang, Mengling; Sun, Minghui Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2486309 PubMed DOI |
| 4. | Real-world data analysis of topotecan in combination with Bevacizumab or CycloPhosphamide in the FDA adverse event reporting system (FAERS) database Author: Chen, Huihui; Zhuang, Guobiao; Hong, Shihao; Wu, Jing Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2488240 PubMed DOI |
| 5. | Adverse events of celecoxib associated with the central nervous system and cancer: a disproportionality analysis of the FDA adverse event reporting system Author: Du, Yikuan; Zhang, Mengting; Chen, Mianhai; Hu, Mianda; Zeng, Wenqi; Cai, Xiaolin; Zhang, Weichui; Zhu, Jinfeng; Zhong, Mingjun; Liu, Yi; Yang, Chun Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2487140 PubMed DOI |
| 6. | Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system Author: Wang, Junyu; Ma, Rong; Qu, Binbin; Li, Xiangpeng Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2487158 PubMed DOI |
| 7. | Analysis of diroximel fumarate data for patients with relapsing forms of multiple sclerosis using related adverse events from the FDA adverse reporting system Author: Yang, Jing-Ya; Sun, Sheng-Zhu; Sun, Yi-Yan; Zuo, Tian-Qi; Li, Xiao-Tong; Zhao, Lei-Yong; Wu, Hong-Yun; Peng, Wei Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2488318 PubMed DOI |
| 8. | A disproportionality analysis of hydrocortisone-related adverse events: a real-world pharmacovigilance study using the FAERS database Author: Wang, Xiaoyu; An, Fan; Zhao, Xuelian; Wang, Benjun; Yan, Liwei; Han, Weiwei Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2487159 PubMed DOI |
| 9. | A real-world disproportionality analysis of cidofovir from the FDA Adverse Event Reporting System (FAERS) database Author: Liu, Chengzhi; Wang, Xinyu; Zhou, Chuanlie; Cao, Xusheng Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2490271 PubMed DOI |
| 10. | Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database Author: Lv, Meina; Chen, Jianhui; Zheng, Bin; Lin, Bijuan; Liu, Maobai Journal: EXPERT OPINION ON DRUG SAFETY. 2025; Vol. , Issue , pp. -. DOI: 10.1080/14740338.2025.2488239 PubMed DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
